Jan 4 Cellectis Sa
* Cellectis submits IND application for UCART123, an allogeneic gene edited car t-cell product candidate, in AML and BPDCN
* Cellectis sa says pending regulatory clearance, plans to initiate phase 1 clinical trials in first half of 2017 Source text for Eikon: Further company coverage:
Macau gambling revenue rises 16.3 pct in April
HONG KONG, May 1Revenue at the world's biggest casino hub of Macau rose 16.3 percent in April, as new resorts helped draw high rollers and casual gamblers to the country's only legal casino hub.